


Module B: Initiation of Therapy



Sidebar 1 - Major Risk factors for CVD

| Non-Modifiable                    | Modifiable                      |
|-----------------------------------|---------------------------------|
| • Increasing age                  | • Tobacco use/Cigarette smoking |
| • Male gender                     | • Dyslipidemia (low HDL-C)      |
| • Family history of premature CVD | • Diabetes Mellitus             |
|                                   | • Hypertension                  |

Risk factors are multiplicative in their effect. Therefore, in the assessment and management of coronary risk in any individual, it is essential to adopt a global approach consisting of an evaluation and treatment of all existing risk factors.

Sidebar 2 - Screening Criteria

- a. Male age 35 or older OR
- b. Female age 45 or older OR
- c. More than one of the following:
- Family history of premature CVD;
  - Patient is smoking or
  - Patient has HTN or is being treated for HTN
- d. Consider obtaining lipid profile for young adults with abdominal obesity

Sidebar 3: Abnormal Lipids

|                        |                          |
|------------------------|--------------------------|
| Total Cholesterol (TC) | ≥240 mg/dL (≥6.2 mmol/L) |
| HDL-Cholesterol        | <40 mg/dL (<1.0 mmol/L)  |
| Triglycerides (TG)     | ≥200 mg/dL (≥2.3 mmol/L) |
| LDL-Cholesterol        | ≥130 mg/dL (≥4.9 mmol/L) |

Sidebar 4 - Lifestyle Modifications

Tobacco use/Smoking cessation

Healthy diet


Increase physical activity

Weight loss, if indicated

Reduce excessive alcohol use

VA/DoD Clinical Practice Guideline  
Management of Dyslipidemia  
Pocket Guide

Module A: Screening




CV - Cardiovascular Disease  
TC - Total Cholesterol  
HDL-C - High Density Lipoprotein Cholesterol  
LDL-C - Low Density Lipoprotein Cholesterol  
TG - Triglycerides

VA access to full guideline: <http://www.oqp.med.va.gov/cpg/cpg.htm>  
DoD access to full guideline: <http://www.qmo.amedd.army.mil>  
Sponsored & produced by the VA Employee Education System in cooperation with the Offices of Quality & Performance and Patient Care Services and the Department of Defense

January 2006



Module C: Follow-up Treatment



| Sidebar 5 - Secondary Causes of Lipid Abnormalities |                              |  |
|---|------------------------------|--|
| Disorder/Patient Characteristic                     | Effect on Lipids             | Laboratory Test                              |
| Chronic renal failure/post renal transplantation    | ↑ TG, ↑ TC, ↓ HDL-C          | S <sub>Cr</sub>                              |
| DM  | ↑ TG, ↑ TC, ↓ HDL-C          | Glucose, HbA1c                               |
| Ethanol use   | ↑ TG, ↑ HDL-C                | —  |
| HIV/AIDS Wasting                                    | ↑ TG, ↓ TC, ↓ HDL-C, ↓ LDL-C | —  |
| HIV/AIDS (HAART)                                    | ↑ TG, ↑ TC, ↑ LDL-C          | —  |
| Hypothyroidism                                      | ↑ TG, ↑ TC, ↑ LDL-C          | TSH  |
| Inactivity  | ↓ HDL-C                      | —  |
| Nephrotic syndrome                                  | ↑ TC, ↑ LDL-C                | Urinalysis, serum albumin                    |
| Obesity   | ↑ TG, ↓ HDL-C                | —  |
| Obstructive liver disease                           | ↑ TC                         | LFTs (Alkaline phosphatase, total bilirubin) |
| Estrogen therapy                                    | ↑ TG, ↓ LDL-C, ↑ HDL-C       | —  |
| Medications   | Variable                     | —  |

AIDS = acquired immune deficiency syndrome; DM = diabetes mellitus; HAART = Highly Active AntiRetroviral Therapy; HbA1c = glycosylated hemoglobin; HDL-C = high-density lipoprotein cholesterol; HIV = human immuno deficiency virus; LDL-C = low-density lipoprotein cholesterol; LFTs = liver function tests; S<sub>Cr</sub> = serum creatinine; TC = total cholesterol; TG = triglycerides; TSH = thyroid-stimulating hormone.

| Sidebar 7 - Essential Components of Therapeutic Lifestyle Changes (TLC) |   |
|---|---|
| Component   | Recommendation  |
| LDL-raising nutrients   |   |
| Saturated fats*   | Less than 7% of total calories  |
| Dietary cholesterol   | Less than 200 mg/day  |
| Therapeutic options for LDL lowering                                    |   |
| Plant stanols/sterols   | 2 grams per day   |
| Increased viscous (soluble) fiber                                       | 10—25 grams per day   |
| Total calories (energy)   | Adjust total caloric intake to maintain desirable body weight/prevent weight gain |
| Physical activity   | Include enough moderate exercise to expend at least 200 kcal per day              |

\*Trans fatty acids are another LDL-raising fat that should be kept at a low intake.

| Sidebar 6 - Summary of Dyslipidemia Therapy Thresholds and Goals |  |                         |     |   |                            |
|--|--|-------------------------|-----|---|----------------------------|
| Risk Category  | Disease Status or Risk Factors                 | Calculated 10-Year Risk | TLC | LDL-C Level for Considering Statin Drug Therapy | LDL Goal of Therapy*       |
| Secondary Prevention   | Recent ACS                                     | N/A                     | All | All   | <100 mg/dL<br><70 optional |
|  | Very high<br>CHD or DM with other risk factors | N/A                     | All | ≥100 mg/dL                                      | < 100 mg/dL                |
|  | DM with no other risk factors                  | N/A                     | All | ≥130 mg/dL<br>100-129 optional                  | <130 mg/dL                 |
| Primary Prevention   | High<br>More than 2 RF                         | ≥ 20%                   | All | ≥130 (or HDL <40)<br>100-129 optional           | <100 mg/dL                 |
|  | Intermediate<br>More than 2 RF                 | 15-20%<br>10-14% **     | All | ≥130 mg/dL<br>≥160 mg/dL                        | <130 mg/dL<br><130 mg/dL   |
|  | Low<br>0 or 1 RF                               | N/A                     | All | ≥190 mg/dL                                      | <160 mg/dL                 |

LDL-C reduction of 30-40% from baseline may be considered an alternative therapeutic strategy for patients who can not meet the above goals.

N/A = Not applicable; TLC = Therapeutic Lifestyle Changes; RF = Risk Factor

\* Lowering absolute risk involves modification of multiple risk factors/co-morbidities, not only LDL-C levels. Therefore, these goals should serve as a general guide and clinical judgment should be used to modify the goals as appropriate for each patient.

\*\* There is insufficient evidence at this time to recommend routine screening for other risk markers not included in the risk index (e.g., FH, hsCRP, metabolic syndrome, depression), or evidence of significant atherosclerotic burden (e.g., high coronary artery calcification scores, intima medial thickness, abnormal brachial reactivity, or abnormal ankle-brachial index). These risk markers may be useful in the intermediate risk patient for whom it is less convincing that drug therapy would have a meaningful impact on outcomes.

| Sidebar 8 - Currently Available Statins to Attain a 30-40% Reduction of LDL-C Levels |              |                  |
|--|--------------|------------------|
| Drug   | Dose, mg/day | LDL Reduction, % |
| Atorvastatin   | 10†          | 39               |
| Lovastatin   | 40†          | 31               |
| Pravastatin  | 40†          | 34               |
| Simvastatin  | 20—40†       | 35—41            |
| Fluvastatin  | 40—80        | 25—35            |
| Rosuvastatin   | 5—10‡        | 39—45            |

\* Estimated LDL reductions were obtained from U.S. Food and Drug Administration (FDA) package inserts for each drug.

† All of these are available at doses up to 80 mg. For every doubling of the dose above standard dose, an approximate 6% decrease in LDL-C level can be obtained.

‡ For rosuvastatin, doses available up to 40 mg; the efficacy for 5 mg is estimated by subtracting 6% from the FDA-reported efficacy at 10 mg. (Jones et al., 1998)